Cti tracker

The Contraceptive Technology Innovation Tracker—CTI Tracker—houses information on potential contraceptive leads in early development, products in pre-clinical and clinical development, and products with single-country regulatory approval. The Tracker reports on both active development platforms and inactive R&D.

Contraceptive Pipeline Baseline Report ⬇ Export Database

For more information about contraceptive R&D, visit our partner databases

Show Filters
Inactive
Last updated: April 9, 2025
Levonorgestrel Intracervical Device (ICD)
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Vaginal - Other
  • Intended Duration: Long-Acting
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): University of Helsinki, Population Council
Inactive
Last updated: April 9, 2025
Levogel

Pericoital LNG Gel

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Vaginal Gel
  • Intended Duration: Pericoital
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): Population Council
Inactive
Last updated: April 9, 2025
Injectable EE + DRSP PLGA Microcapsules
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Long-Acting
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Bayer
Inactive
Last updated: April 9, 2025
In-Situ Forming Gel (UTHSC)
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): University of Tennessee Health Sciences Center
Inactive
Last updated: April 9, 2025
Gamma Irradiated Injectable LNG Microparticles
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Undetermined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): University of Mumbai
Inactive
Last updated: April 9, 2025
Gamma Butyrolactone Derivatives
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Undetermined
  • Intended Duration: Pericoital
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Central Drug Research Institute, India
Inactive
Last updated: April 9, 2025
FSHβ-Melphalan Conjugates
  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Permanent
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): University of Washington, Focused Scientific
Inactive
Last updated: April 9, 2025
Faslodex Spermiogenesis Inhibitor

Antiestrogen ICI 182780, Fulvestrant

  • User: Male
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): University of Illinois
Inactive
Last updated: April 8, 2025
Doughnut Microspheres with PMCA Inhibitors

Plasma Membrane Calcium ATPase (PMCA) Inhibitors

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Multiple
  • Intended Duration: Short-Acting
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): University of Manchester, Max Planck Institute
Inactive
Last updated: April 8, 2025
DMPA + Testosterone

Depot Medroxyprogesterone Acetate + Testosterone

  • User: Male
  • Hormonal: Hormonal
  • Delivery Type: Multiple
  • Intended Duration: Short-Acting
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): ANZAC Research Institute